Robecosam AG purchased a new stake in Celgene Co. (NASDAQ:CELG) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 800 shares of the biopharmaceutical company’s stock, valued at approximately $114,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Counsel LLC NY raised its position in shares of Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC raised its position in shares of Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 11 shares during the last quarter. Savant Capital LLC raised its position in shares of Celgene by 0.9% in the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. raised its position in shares of Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 26 shares during the last quarter. Finally, Granite Investment Advisors LLC raised its position in shares of Celgene by 1.1% in the second quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 29 shares during the last quarter. 79.54% of the stock is currently owned by institutional investors.

A number of equities analysts have recently weighed in on CELG shares. Morgan Stanley lowered shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Thursday, October 5th. Sanford C. Bernstein lowered shares of Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price objective for the company. in a research report on Wednesday, December 27th. BTIG Research reissued a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 price target on shares of Celgene in a research report on Monday, October 30th. Finally, Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $129.98.

Shares of Celgene Co. (NASDAQ:CELG) opened at $102.65 on Monday. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The stock has a market cap of $80,818.09, a price-to-earnings ratio of 24.38, a PEG ratio of 0.65 and a beta of 1.77. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the prior year, the business earned $1.58 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. research analysts forecast that Celgene Co. will post 6.71 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “800 Shares in Celgene Co. (CELG) Acquired by Robecosam AG” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://theolympiareport.com/2018/01/22/800-shares-in-celgene-co-celg-acquired-by-robecosam-ag.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.